Skip to Main Content

Paper Details

Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial.
Eur Heart J
4
2022
CAD, ICH, MACE, PAD, People, Rivaroxaban, aspirin, atherosclerotic vascular disease, chronic CAD, chronic coronary artery disease, intracranial haemorrhage, patients, peripheral arterial disease, peripheral artery disease, rivaroxaban
Author NameAffiliation
Deepak L BhattBrigham and Women's Hospital, Harvard Medical School
Keith A A FoxUniversity of Edinburgh
Salim YusufMcMaster University
Salim YusufPopulation Health Research Institute
Salim Yusuf
  • 1 - 5

Datasets

Release 1.2